UA117933C2 - Поліпептид, здатний зв'язувати с5-компонент комплементу людини - Google Patents

Поліпептид, здатний зв'язувати с5-компонент комплементу людини

Info

Publication number
UA117933C2
UA117933C2 UAA201603124A UAA201603124A UA117933C2 UA 117933 C2 UA117933 C2 UA 117933C2 UA A201603124 A UAA201603124 A UA A201603124A UA A201603124 A UAA201603124 A UA A201603124A UA 117933 C2 UA117933 C2 UA 117933C2
Authority
UA
Ukraine
Prior art keywords
human complement
polypeptides binding
stable polypeptides
binding
stable
Prior art date
Application number
UAA201603124A
Other languages
English (en)
Inventor
Йоаким Нільссон
Ерік Нордлінг
Патрік Стрьомберг
Original Assignee
Сведіш Орфан Біовітрум Аб (Пабл)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сведіш Орфан Біовітрум Аб (Пабл) filed Critical Сведіш Орфан Біовітрум Аб (Пабл)
Publication of UA117933C2 publication Critical patent/UA117933C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Винахід належить до поліпептиду, здатного зв'язуватися з компонентом 5 комплементу людини (С5), сполуки, що здатна зв’язувати С5, та до зазначеного поліпептиду та зазначеної сполуки для застосування для лікування С5-пов’язаних станів.
UAA201603124A 2013-08-28 2014-08-28 Поліпептид, здатний зв'язувати с5-компонент комплементу людини UA117933C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1350986 2013-08-28
PCT/EP2014/068282 WO2015028558A1 (en) 2013-08-28 2014-08-28 Stable polypeptides binding to human complement c5

Publications (1)

Publication Number Publication Date
UA117933C2 true UA117933C2 (uk) 2018-10-25

Family

ID=51539238

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201603124A UA117933C2 (uk) 2013-08-28 2014-08-28 Поліпептид, здатний зв'язувати с5-компонент комплементу людини

Country Status (29)

Country Link
US (1) US9994626B2 (uk)
EP (2) EP3811961A1 (uk)
JP (2) JP6767865B2 (uk)
KR (1) KR102446636B1 (uk)
CN (1) CN105658228B (uk)
AU (1) AU2014314222B2 (uk)
BR (2) BR112016003142A2 (uk)
CA (1) CA2926976C (uk)
CY (1) CY1123732T1 (uk)
DK (1) DK3038633T3 (uk)
ES (1) ES2842105T3 (uk)
HK (1) HK1225656A1 (uk)
HR (1) HRP20210013T1 (uk)
HU (1) HUE052613T2 (uk)
IL (1) IL244218A (uk)
LT (1) LT3038633T (uk)
MX (1) MX2016002397A (uk)
MY (1) MY173804A (uk)
NZ (1) NZ718153A (uk)
PH (1) PH12016500371B1 (uk)
PL (1) PL3038633T3 (uk)
PT (1) PT3038633T (uk)
RS (1) RS61347B1 (uk)
RU (2) RU2733897C2 (uk)
SA (1) SA516370622B1 (uk)
SG (1) SG11201602679VA (uk)
SI (1) SI3038633T1 (uk)
UA (1) UA117933C2 (uk)
WO (1) WO2015028558A1 (uk)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126006A1 (en) * 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
TR201911279T4 (tr) 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.
WO2015028558A1 (en) * 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
CN117327187A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
WO2023077139A1 (en) * 2021-11-01 2023-05-04 Ipc Research, Llc Administration of c5-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
JP4958387B2 (ja) 2001-08-17 2012-06-20 ジェネンテック， インコーポレイテッド Ｃ５ｂの形成を妨害することなくｃ５及びｃ５ａに結合する補体経路阻害剤
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
EP1667702A2 (en) * 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
SE0400274D0 (sv) * 2004-02-09 2004-02-09 Affibody Ab New polypeptide
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
CA3148917A1 (en) * 2006-03-08 2007-09-13 Archemix Llc Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
DK2359834T5 (en) 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
AU2008281913B2 (en) 2007-07-31 2013-11-07 Affibody Ab New albumin binding compositions, methods and uses
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
EP2072525A1 (en) 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
PL2328616T3 (pl) 2008-08-05 2015-10-30 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
JP5827994B2 (ja) * 2010-07-09 2015-12-02 アフィボディ・アーベー ポリペプチド
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
JP5980104B2 (ja) 2012-11-22 2016-08-31 三菱電機株式会社 液晶表示装置の製造方法および液晶表示装置の製造システム
US9957330B2 (en) 2012-12-19 2018-05-01 Affibody Ab Polypeptides
WO2015028558A1 (en) * 2013-08-28 2015-03-05 Swedish Orphan Biovitrum Ab (Publ) Stable polypeptides binding to human complement c5
TR201911279T4 (tr) 2013-08-28 2019-08-21 Affibody Ab Mutasyona uğramış bir yapı iskelesine sahip polipeptidlerin bağlanması.

Also Published As

Publication number Publication date
WO2015028558A1 (en) 2015-03-05
US20160311870A1 (en) 2016-10-27
IL244218A (en) 2017-11-30
US9994626B2 (en) 2018-06-12
NZ718153A (en) 2022-05-27
CA2926976A1 (en) 2015-03-05
MY173804A (en) 2020-02-24
CN105658228A (zh) 2016-06-08
SG11201602679VA (en) 2016-05-30
AU2014314222B2 (en) 2018-05-24
BR112016003142A2 (pt) 2017-10-17
EP3038633A1 (en) 2016-07-06
HK1225656A1 (zh) 2017-09-15
RU2016111115A3 (uk) 2018-04-25
PH12016500371A1 (en) 2016-05-02
PH12016500371B1 (en) 2016-05-02
JP2020172505A (ja) 2020-10-22
KR20160048121A (ko) 2016-05-03
IL244218A0 (en) 2016-04-21
CA2926976C (en) 2023-11-28
KR102446636B1 (ko) 2022-09-23
LT3038633T (lt) 2021-03-25
PL3038633T3 (pl) 2021-07-19
PT3038633T (pt) 2021-01-14
HUE052613T2 (hu) 2021-05-28
RS61347B1 (sr) 2021-02-26
EP3811961A1 (en) 2021-04-28
ES2842105T3 (es) 2021-07-12
JP2016529270A (ja) 2016-09-23
RU2016111115A (ru) 2017-10-03
SA516370622B1 (ar) 2018-12-23
EP3038633B1 (en) 2020-10-14
CY1123732T1 (el) 2021-10-29
DK3038633T3 (da) 2021-01-11
RU2733897C2 (ru) 2020-10-09
HRP20210013T1 (hr) 2021-04-02
CN105658228B (zh) 2020-02-07
RU2020128977A (ru) 2021-11-30
AU2014314222A1 (en) 2016-04-21
SI3038633T1 (sl) 2021-05-31
BR122023020080A2 (pt) 2023-12-26
MX2016002397A (es) 2016-09-08
JP6767865B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
CY1122898T1 (el) Απεκκριση πολυπεπτιδιων που περιεχουν αιμη
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
PH12016501644B1 (en) Binding proteins and methods of use thereof
EA201591559A1 (ru) Терапевтические пептиды
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA201890204A1 (ru) Антибактериальные соединения
UA118558C2 (uk) Пептидна сполука
EA201591137A1 (ru) Ингибиторы mk2 и их применения
BR112016023948A2 (pt) proteínas fc multiméricas
EA201690314A1 (ru) Анти-garp-белок и его применения
MX2016007063A (es) Peptidos terapeuticos.
PH12016500137A1 (en) Afucosylated anti-fgfr2iiib antibodies
EA201792348A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201591839A1 (ru) Терапевтические пептиды
EA201690613A1 (ru) Улучшенные составы на основе аденовирусов
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA202090683A3 (ru) Способы и композиции для лечения рака
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201690036A1 (ru) Состав с отсроченным высвобождением, содержащий гранулы цистеамина, и способы его получения и применения
ZA201803551B (en) Personal care composition comprising taurine, arginine, glycine